2. UroToday Home
  3. Tags

Translational Science In Prostate Cancer COE Articles

Articles

  • ASTRO 2024: Precision in Practice: Optimizing Prostate Radiation with MRI-Defined Microboost

    (UroToday.com) The 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting held in Washington, DC, was host to a presidential symposium of innovations in genitourinary cancers, specifically addressing radiotherapy innovations for prostate cancer that can be implemented in contemporary practice. Dr. Brandon Mahal discussed optimizing prostate radiation dosage and precision using an MRI-defined microboost.
    Published September 29, 2024

  • Evaluation of Social Determinants of Health and Prostate Cancer Outcomes Among Black and White Patients: A Systematic Review and Meta-analysis - Beyond the Abstract

    Immense resources have been dedicated to identifying innate biological differences between Black and White men that could explain the disparities in prostate cancer with the results being equivocal at best. Prostate cancer, the most commonly diagnosed solid organ cancer in men, represents perhaps the greatest disparity in outcomes in oncology.1 Few studies, if any, have attempted to evaluate the association between prostate cancer outcomes and social determinants of health (SDOH). The Department of Health and Human Services (HHS) defines SDOH as "the conditions in the environments where people are born, live, learn, work, play, worship and age that affect a wide range of health, functioning, and quality-of-life outcomes and risks".2 With the historical and continued oppression of Black people that transcends income and educational level, evaluating the association between SDOH and disparities in healthcare outcomes is crucial to determine initiatives to mitigate these continued inequities.
    Published March 31, 2023

  • Price Transparency of Prostate Cancer Care in the United States: An Analysis of Pricing and Disclosure Following the Centers for Medicare and Medicaid Mandate - Beyond the Abstract

    The costs incurred for healthcare have historically been opaque, such that patients are often unaware of their treatment costs until their bills come due. To ameliorate this, the Centers for Medicare and Medicaid Services issued a mandate that starting on January 1, 2021, all hospitals in the United States must make the pricing of provided services publicly available on their hospital websites in machine-readable files. We used a dataset that aggregates these publicly-displayed prices to investigate the landscape of pricing for prostate cancer care.
    Published February 27, 2023

  • Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Men with Non-Metastatic Castration-Resistant Prostate Cancer – Beyond the Abstract

    In castration-resistant prostate cancer (CRPC), tumor progression occurs despite low, castrate levels of serum testosterone.1 Non-metastatic CRPC (nmCRPC) is characterized by the absence of detectable metastases and prostate-specific antigen (PSA) levels that continue to rise even though patients continue to receive androgen-deprivation therapy.2 Patients with nmCRPC are at risk of progression to metastatic disease and nmCRPC patients with shorter PSA doubling time (PSADT) have increased risk of metastasis and poorer clinical outcomes.3–5
    Published May 3, 2023

  • Treatment of Prostate Cancer With CD46 Targeted 225ac Alpha Particle Radio-Immunotherapy - Beyond the Abstract

    Targeted radionuclide therapy is an emerging strategy for treating genitourinary malignancies. PSMA-targeted radiolabeled molecules have shown promising results for both imaging and radiopharmaceutical therapy in prostate cancer. However, a significant fraction of patients are negative for PSMA or develop PSMA negativity during treatment, leading to a lack of response to PSMA-directed radioligand theranostic molecules.
    Published April 11, 2023